CD19 and Hyperglycemia: Significantly upregulated genes after RvE1 treatment such as differentiation antigen CD19 (Cd19, Log2FC = 1.37), neuronal pentraxin 1 (Nptx1, Log2FC = 2.01), phosphodiesterase 6C (Pde6c, Log2FC = 1.0), and BCL2 binding component 3 (Bbc3, Log2FC = 0.59) are associated with multiple pathways spanning hyperglycemia, p53 signaling, and apoptosis (46, 55, 56).